Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
scientific article published on 17 February 2014
Author/s
author: Robert Motzer, Georg A. Bjarnason, Camillo Porta, Sun Young Rha, Emilio Esteban, Cezary Szczylik, Ugo De Giorgi, Cora Sternberg, Nicholas J. Vogelzang, Christian Kollmannsberger
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.